BRPI0417987A - agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica - Google Patents
agentes para o tratamento de retinopatia glaucomatosa e de neuropatia ópticaInfo
- Publication number
- BRPI0417987A BRPI0417987A BRPI0417987-0A BRPI0417987A BRPI0417987A BR PI0417987 A BRPI0417987 A BR PI0417987A BR PI0417987 A BRPI0417987 A BR PI0417987A BR PI0417987 A BRPI0417987 A BR PI0417987A
- Authority
- BR
- Brazil
- Prior art keywords
- agents
- treatment
- optic neuropathy
- glaucomatous retinopathy
- nrf2
- Prior art date
Links
- 206010061323 Optic neuropathy Diseases 0.000 title abstract 3
- 208000017442 Retinal disease Diseases 0.000 title abstract 3
- 206010038923 Retinopathy Diseases 0.000 title abstract 3
- 208000020911 optic nerve disease Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 abstract 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 abstract 1
- LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 239000004258 Ethoxyquin Substances 0.000 abstract 1
- 238000006845 Michael addition reaction Methods 0.000 abstract 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 abstract 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 abstract 1
- 230000001120 cytoprotective effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000007123 defense Effects 0.000 abstract 1
- 239000012039 electrophile Substances 0.000 abstract 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 abstract 1
- 235000019285 ethoxyquin Nutrition 0.000 abstract 1
- 229940093500 ethoxyquin Drugs 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 150000002540 isothiocyanates Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005937 nuclear translocation Effects 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000002676 xenobiotic agent Substances 0.000 abstract 1
- 230000002034 xenobiotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53177003P | 2003-12-22 | 2003-12-22 | |
| PCT/US2004/042687 WO2005063295A1 (en) | 2003-12-22 | 2004-12-17 | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0417987A true BRPI0417987A (pt) | 2007-04-27 |
Family
ID=34738696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417987-0A BRPI0417987A (pt) | 2003-12-22 | 2004-12-17 | agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050137146A1 (https=) |
| EP (2) | EP1696958B1 (https=) |
| JP (2) | JP4755599B2 (https=) |
| KR (1) | KR20060127043A (https=) |
| CN (1) | CN1897972A (https=) |
| AT (2) | ATE523208T1 (https=) |
| AU (1) | AU2004308919B2 (https=) |
| BR (1) | BRPI0417987A (https=) |
| CA (1) | CA2547852A1 (https=) |
| CY (2) | CY1106623T1 (https=) |
| DE (1) | DE602004005617T2 (https=) |
| DK (2) | DK1803468T3 (https=) |
| ES (2) | ES2371364T3 (https=) |
| MX (1) | MXPA06006980A (https=) |
| PL (2) | PL1696958T3 (https=) |
| PT (2) | PT1803468E (https=) |
| SI (2) | SI1696958T1 (https=) |
| WO (1) | WO2005063295A1 (https=) |
| ZA (1) | ZA200604862B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881198B2 (en) * | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
| PL1696958T3 (pl) * | 2003-12-22 | 2007-08-31 | Alcon Inc | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej |
| WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| WO2006030907A1 (ja) * | 2004-09-16 | 2006-03-23 | Redox Bioscience Inc. | 網膜保護剤 |
| CA2621993A1 (en) * | 2005-09-16 | 2007-03-29 | Bg Implant, Inc. | Glaucoma treatment devices and methods |
| WO2008016095A1 (en) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| US8022246B2 (en) * | 2006-10-10 | 2011-09-20 | The Burnham Institute For Medical Research | Neuroprotective compositions and methods |
| WO2008111497A1 (ja) * | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| RS55631B1 (sr) | 2008-04-18 | 2017-06-30 | Reata Pharmaceuticals Inc | Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline |
| WO2009129546A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| MX357596B (es) | 2010-04-12 | 2018-07-16 | Reata Pharmaceuticals Inc | Método para tratar obesidad utilizando moduladores de inflamación con antioxidantes. |
| RU2472475C2 (ru) * | 2010-04-20 | 2013-01-20 | Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) | Способ комбинированного лечения глаукомной оптической нейропатии |
| WO2012009171A2 (en) * | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| RU2447864C1 (ru) * | 2010-09-15 | 2012-04-20 | Инна Витальевна Щербинина | Способ лечения заболеваний зрительного нерва и сетчатки |
| CN103702669A (zh) * | 2011-06-21 | 2014-04-02 | 约翰霍普金斯大学 | 用于治疗周围神经病变和其他神经退行性疾患的化合物 |
| RU2546019C2 (ru) * | 2013-03-02 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ лечения глаукомной оптической нейропатии |
| EP2991621B1 (en) | 2013-05-02 | 2020-12-09 | Retina Foundation of the Southwest | Two-layer ocular implant |
| JP7030516B2 (ja) | 2014-12-31 | 2022-03-07 | マイクロオプティクス インコーポレイテッド | 緑内障治療装置および方法 |
| AU2016331925B2 (en) | 2015-09-30 | 2021-04-22 | Microoptx Inc. | Dry eye treatment devices and methods |
| EP3509641A1 (en) | 2016-09-12 | 2019-07-17 | ST IP Holding AG | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
| JP2019531344A (ja) | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
| KR102486434B1 (ko) | 2016-11-08 | 2023-01-09 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법 |
| RU2647324C1 (ru) * | 2017-04-24 | 2018-03-15 | Игорь Евгеньевич Хаценко | Способ определения показаний для лечения амблиопии с помощью нейропептидного препарата |
| JP2023528139A (ja) * | 2020-03-30 | 2023-07-04 | ウーハン ニューロフス バイオテクノロジー リミテッド カンパニー | ヒト核因子ｅ２関連因子２の発現ベクター及び発現ベクターの適用 |
| US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| CA2175985A1 (en) * | 1995-05-10 | 1996-11-11 | Yoichi Kiyosuke | Pharmaceutical composition containing substance inhibiting hsp47 production |
| JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質ｐ１６０ |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| PT868186E (pt) * | 1995-12-21 | 2005-05-31 | Alcon Lab Inc | Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular |
| ATE247090T1 (de) * | 1996-02-02 | 2003-08-15 | Hidaka Hiroyoshi Dr | Isochinolinderivate und arzneimittel |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| JP3872834B2 (ja) * | 1996-03-04 | 2007-01-24 | 第一製薬株式会社 | メイラード反応抑制剤 |
| NZ513800A (en) * | 1996-08-12 | 2001-09-28 | Welfide Corp | Treatment of diseases using Rho kinase inhibitors |
| US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
| AU719764B2 (en) * | 1997-01-16 | 2000-05-18 | University Of Florida Research Foundation, Inc. | Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
| US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
| US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| WO1999043315A1 (en) * | 1998-02-25 | 1999-09-02 | Shionogi & Co., Ltd. | Therapeutic agent for complication of diabetes |
| US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
| US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
| GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
| US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
| CA2357265C (en) * | 2001-04-24 | 2004-04-13 | University Of British Columbia | Improved additive for livestock feeds |
| US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| TW201041580A (en) * | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| US7199122B2 (en) * | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| EP1474158B1 (en) * | 2001-12-18 | 2009-10-14 | Brassica Foundation for Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes |
| WO2003068202A1 (en) * | 2002-02-15 | 2003-08-21 | Dsm Ip Assets B.V. | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| TW200407119A (en) * | 2002-08-05 | 2004-05-16 | Kin-Ping Wong | Methods and compositions to treat conditions associated with neovascularization |
| US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| EP1696926A1 (en) * | 2003-12-22 | 2006-09-06 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| PL1696958T3 (pl) * | 2003-12-22 | 2007-08-31 | Alcon Inc | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej |
-
2004
- 2004-12-17 PL PL04814825T patent/PL1696958T3/pl unknown
- 2004-12-17 PT PT07105047T patent/PT1803468E/pt unknown
- 2004-12-17 ZA ZA200604862A patent/ZA200604862B/en unknown
- 2004-12-17 JP JP2006545535A patent/JP4755599B2/ja not_active Expired - Fee Related
- 2004-12-17 PL PL07105047T patent/PL1803468T3/pl unknown
- 2004-12-17 SI SI200430296T patent/SI1696958T1/sl unknown
- 2004-12-17 CA CA002547852A patent/CA2547852A1/en not_active Abandoned
- 2004-12-17 EP EP04814825A patent/EP1696958B1/en not_active Expired - Lifetime
- 2004-12-17 DK DK07105047.0T patent/DK1803468T3/da active
- 2004-12-17 MX MXPA06006980A patent/MXPA06006980A/es active IP Right Grant
- 2004-12-17 ES ES07105047T patent/ES2371364T3/es not_active Expired - Lifetime
- 2004-12-17 KR KR1020067014097A patent/KR20060127043A/ko not_active Ceased
- 2004-12-17 AT AT07105047T patent/ATE523208T1/de active
- 2004-12-17 EP EP07105047A patent/EP1803468B1/en not_active Expired - Lifetime
- 2004-12-17 DK DK04814825T patent/DK1696958T3/da active
- 2004-12-17 CN CNA2004800384580A patent/CN1897972A/zh active Pending
- 2004-12-17 US US11/015,888 patent/US20050137146A1/en not_active Abandoned
- 2004-12-17 AU AU2004308919A patent/AU2004308919B2/en not_active Ceased
- 2004-12-17 PT PT04814825T patent/PT1696958E/pt unknown
- 2004-12-17 AT AT04814825T patent/ATE357932T1/de active
- 2004-12-17 BR BRPI0417987-0A patent/BRPI0417987A/pt not_active IP Right Cessation
- 2004-12-17 ES ES04814825T patent/ES2282926T3/es not_active Expired - Lifetime
- 2004-12-17 DE DE602004005617T patent/DE602004005617T2/de not_active Expired - Lifetime
- 2004-12-17 SI SI200431767T patent/SI1803468T1/sl unknown
- 2004-12-17 WO PCT/US2004/042687 patent/WO2005063295A1/en not_active Ceased
-
2007
- 2007-05-25 CY CY20071100711T patent/CY1106623T1/el unknown
-
2010
- 2010-11-04 JP JP2010247809A patent/JP2011046736A/ja not_active Withdrawn
-
2011
- 2011-02-22 US US13/031,742 patent/US20110144127A1/en not_active Abandoned
- 2011-11-24 CY CY20111101143T patent/CY1112393T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417987A (pt) | agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica | |
| BRPI0417996A (pt) | agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular | |
| BR0010555A (pt) | Inibidores de neuraminidases | |
| UY38382A (es) | Agentes de arni para inhibir la expresión de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y métodos de uso | |
| BRPI0415622A (pt) | linhas de células aviárias importalizadas para produção de vìrus | |
| UY27891A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para la preparación de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos. | |
| BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
| BR0312695A (pt) | Derivados de 1h-pirrolidina-2,4-diona espirocìclicos substituìdos por cis-alcóxi | |
| BRPI0513086A (pt) | 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos | |
| AR013001A1 (es) | Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina. | |
| AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| GT199800142A (es) | Pirimidin-4-ona y pirimidin-4-tiona novedosas como fungicida. | |
| ECSP045353A (es) | Derivados de benzoxazinona, su preparación y aplicación como medicamentos | |
| BRPI0607927A2 (pt) | derivados de pirazol-pirimidina | |
| BRPI0905687A8 (pt) | composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto | |
| AR049518A1 (es) | Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados | |
| BRPI0507830A (pt) | derivados azabicìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm | |
| BR0314195A (pt) | Derivados de piridina substituìda como agentes antitumorais | |
| BRPI0409398A (pt) | preventivo e/ou remédio para doenças do nervo retinal | |
| BR0202064A (pt) | Método para identificação de um peptìdeo artimicrobiano, peptìdeo antimicrobiano isolado, análogos dos peptìdeos, seus usos, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, método para prevenir o crescimento, inibir o crescimento ou reduzir a viabilidade de um microorganismo e método de tratamento de um organismo infectado com um microorganismo patogênico | |
| GT200800066A (es) | Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento. | |
| BRPI0511398A (pt) | composição farmacêutica anidra para o tratamento da psorìase e uso de um agente siliconado | |
| BR0010525A (pt) | cido 1-ciclo-hexeno-1-carboxìlico e 1-ciclo-hexeno-1carboxilatos como inibidores de neuraminidase | |
| BRPI0715740A8 (pt) | Agente redutor de triglicerídeos séricos | |
| ES2062570T3 (es) | L-alfa-glicerofosforil-d-mio-inositol para el tratamiento de neuropatias perifericas y de cerebropatias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |